A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects With Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HU 6 (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms M-ACCEL trial
Sponsors Rivus Pharmaceuticals

Most Recent Events

18 Apr 2025 Planned End Date changed from 1 Apr 2025 to 1 Jun 2025.
08 Jan 2025 According to a Rivus Pharmaceuticals media release, topline data expected in the second quarter of 2025.
13 Aug 2024 According to a Rivus Pharmaceuticals media release, Rivus remains on track to announce topline results from the M-ACCEL study in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight